XML 66 R52.htm IDEA: XBRL DOCUMENT v3.21.1
ACQUISITIONS - Narrative (Details)
€ in Millions
3 Months Ended
Mar. 04, 2021
USD ($)
Mar. 04, 2021
EUR (€)
Oct. 23, 2020
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Mar. 04, 2021
EUR (€)
Three-Year Senior Term Loan Facility | Medium-term Notes            
Business Combination, Separately Recognized Transactions [Line Items]            
Borrowing from senior unsecured term loan facility         $ 1,000,000,000.0  
MYR GmbH            
Business Combination, Separately Recognized Transactions [Line Items]            
Acquisition-related expenses       $ 11,000,000    
Acquisition consideration transferred $ 1,600,000,000 € 1,300        
Cash paid for acquisition 1,200,000,000 € 1,000        
Fair value of contingent liability 341,000,000          
Finite-lived intangible assets 845,000,000          
Goodwill 226,000,000          
Expected tax deductible goodwill       $ 0    
MYR GmbH | Maximum            
Business Combination, Separately Recognized Transactions [Line Items]            
Liability for MYR contingent consideration | €           € 300
MYR GmbH | Hepcludex For HDV            
Business Combination, Separately Recognized Transactions [Line Items]            
Finite-lived intangible assets $ 845,000,000          
Weighted average useful life 10 years 10 years        
MYR GmbH | Hepcludex For HDV | Discount Rate            
Business Combination, Separately Recognized Transactions [Line Items]            
Measurement input 0.12         0.12
MYR GmbH | Acquired IPR&D            
Business Combination, Separately Recognized Transactions [Line Items]            
Acquired IPR&D $ 1,190,000,000          
MYR GmbH | Acquired IPR&D | Discount Rate            
Business Combination, Separately Recognized Transactions [Line Items]            
Measurement input 0.12         0.12
Immunomedics            
Business Combination, Separately Recognized Transactions [Line Items]            
Acquisition consideration transferred     $ 20,600,000,000      
Goodwill     3,991,000,000      
Immunomedics | Acquired IPR&D            
Business Combination, Separately Recognized Transactions [Line Items]            
Acquired IPR&D     $ 15,760,000,000